^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    7d
    Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science. (PubMed, Clin Transl Sci)
    Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate (ADC) composed of the DM4 payload conjugated to a folate receptor α (FRα)-targeting antibody via the cleavable sulfo-SPDB linker. The MIRV Phase 3 registrational trial (MIRASOL) showed superiority of MIRV vs. chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) in patients with high (≥ 75%) FRα-expression PROC, showing an objective response rate of 42% versus 16%, a median progression-free survival of 5.6 versus 4.0 months, and an overall survival of 16.5 versus 12.8 months. Here, we briefly review MIRV mechanism of action, pharmacokinetics, pharmacodynamics, and key clinical efficacy and safety data.
    Review • Journal
    |
    FOLR1 ( Folate receptor alpha ) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan
    7d
    Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, University of California, Davis | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial primary completion date • HEOR
    |
    CD4 (CD4 Molecule)
    8d
    EFFORT: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=96, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)
    10d
    REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=860, Recruiting, Daiichi Sankyo | Trial completion date: Dec 2029 --> Apr 2030
    Trial completion date • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    10d
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | N=50 --> 30
    Enrollment change
    |
    carboplatin • paclitaxel • IMNN-001
    13d
    Performance of the VENTANA FOLR1 Assay for folate receptor alpha: Real-world evidence from 313 Chinese participants. (PubMed, Pathol Res Pract)
    Additionally, we conducted a systematic investigation into the associations between FRα expression and clinicopathological characteristics, highlighting its capacity to reflect FRα heterogeneity, maintain stability in post-chemotherapy FRα expression across various tumor types, and achieve robust performance in excision/resection samples. These findings underscore the value of standardizing FRα testing to improve patient selection for FRα-targeted MIRV therapies in China.
    Journal • HEOR • Real-world evidence
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    VENTANA FOLR1 RxDx Assay
    14d
    Using Aspirin to Improve Immunological Features of Ovarian Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    aspirin
    14d
    Risk reduction bilateral salpingo-oophorectomy with vNOTES: A new era in cancer prevention strategies. (PubMed, Surg Oncol)
    Prophylactic bilateral salpingo-oophorectomy using the vNOTES technique appears to be a feasible and safe option for reducing the risk of ovarian and fallopian tube cancers in high-risk women. Further studies with larger cohorts are needed to validate these findings.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    15d
    A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Bio-Thera Solutions | N=170 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Platinum resistant
    15d
    CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, TORL Biotherapeutics, LLC
    New P1/2 trial
    |
    CLDN6 (Claudin 6)
    |
    carboplatin • paclitaxel • ixotatug vedotin (TORL-1-23)
    15d
    RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=43, Completed, RemeGen Co., Ltd. | Recruiting --> Completed | N=88 --> 43 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Platinum resistant
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)